Citizens Financial Group Inc. RI Sells 7,749 Shares of Merck & Co., Inc. $MRK

Key Points

• Citizens Financial Group reduced its Merck position by 2.9% in the second quarter, selling 7,749 shares and retaining 261,913 shares valued at approximately $33.7 million. Institutional investors collectively own 76.07% of MRK.
• Merck’s outlook received support from positive Phase 3 melanoma-treatment results involving Moderna and KEYTRUDA, while analysts raised price targets and maintained a generally bullish view. However, the cancer-vaccine opportunity faces commercialization uncertainties.
• MRK shares opened at $153.21 near their 52-week high of $156.92. The company reported quarterly revenue of $16.61 billion, raised no guidance in the article beyond fiscal 2026 EPS of $2.660–$2.760, and declared a quarterly dividend of $0.85 per share.

Citizens Financial Group Inc. RI reduced its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 261,913 shares of the company's stock after selling 7,749 shares during the quarter. Citizens Financial Group Inc. RI's holdings in Merck & Co., Inc. were worth $33,656,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of MRK. Brighton Jones LLC increased its stake in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its stake in Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock worth $910,000 after acquiring an additional 3,941 shares during the period. Diversify Advisory Services LLC lifted its stake in Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock worth $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock valued at $53,918,000 after acquiring an additional 359,356 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last 90 days. 0.17% of the stock is currently owned by company insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $153.21 on Thursday. The business has a fifty day moving average price of $130.39 and a 200-day moving average price of $122.04. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a market capitalization of $378.00 billion, a PE ratio of 122.57, a PEG ratio of 6.56 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.'s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

Analyst Ratings Changes

Several research analysts have commented on MRK shares. BMO Capital Markets upped their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Wolfe Research lifted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a research note on Tuesday. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 8th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, CICC Research started coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price objective for the company. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $147.60.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source